Mineralys Therapeutics (MLYS) News Today $9.44 -0.09 (-0.94%) As of 02:35 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period HC Wainwright Reiterates Buy Rating for Mineralys Therapeutics (NASDAQ:MLYS)February 15, 2025 | americanbankingnews.comMineralys Therapeutics (NASDAQ:MLYS) Shares Gap Down on Analyst DowngradeFebruary 14, 2025 | americanbankingnews.comMineralys Therapeutics, Inc. (MLYS) Gets a Buy from Goldman SachsFebruary 14, 2025 | markets.businessinsider.comMineralys Therapeutics Highlights Positive Earnings CallFebruary 13, 2025 | tipranks.comMineralys Therapeutics (NASDAQ:MLYS) Shares Gap Down Following Analyst DowngradeMineralys Therapeutics (NASDAQ:MLYS) Shares Gap Down After Analyst DowngradeFebruary 13, 2025 | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Price Target Cut to $24.00 by Analysts at The Goldman Sachs GroupThe Goldman Sachs Group reduced their price target on shares of Mineralys Therapeutics from $28.00 to $24.00 and set a "buy" rating on the stock in a research report on Thursday.February 13, 2025 | marketbeat.comMineralys Therapeutics, Inc. (NASDAQ:MLYS) Q4 2024 Earnings Call TranscriptFebruary 13, 2025 | msn.comMineralys Therapeutics' (MLYS) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright restated a "buy" rating and issued a $30.00 price objective on shares of Mineralys Therapeutics in a research report on Thursday.February 13, 2025 | marketbeat.comQ4 2024 Mineralys Therapeutics Inc Earnings CallFebruary 13, 2025 | finance.yahoo.comMineralys Therapeutics Delivers Financial Update and Advances Pipeline for LorundrostatFebruary 13, 2025 | msn.comMineralys Therapeutics (NASDAQ:MLYS) Shares Gap Up Following Better-Than-Expected EarningsFebruary 13, 2025 | americanbankingnews.comMineralys Therapeutics Reports 2024 Earnings and Trial ProgressFebruary 12, 2025 | tipranks.comMineralys Therapeutics sees cash runway through 1Q26February 12, 2025 | markets.businessinsider.comMineralys Therapeutics reports Q4 EPS (98c), consensus ($1.08)February 12, 2025 | markets.businessinsider.comMineralys Therapeutics, Inc. (MLYS) Q4 2024 Earnings Call TranscriptFebruary 12, 2025 | seekingalpha.comMineralys Therapeutics (NASDAQ:MLYS) Shares Gap Up After Better-Than-Expected EarningsMineralys Therapeutics (NASDAQ:MLYS) Shares Gap Up on Strong EarningsFebruary 12, 2025 | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Posts Earnings Results, Beats Expectations By $0.02 EPSMineralys Therapeutics (NASDAQ:MLYS - Get Free Report) posted its quarterly earnings data on Wednesday. The company reported ($0.98) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.00) by $0.02.February 12, 2025 | marketbeat.comMineralys Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateFebruary 12, 2025 | globenewswire.comMineralys Therapeutics (MLYS) to Release Earnings on WednesdayMineralys Therapeutics (NASDAQ:MLYS) will be releasing earnings before the market opens on Wednesday, February 12.February 8, 2025 | marketbeat.comMineralys Therapeutics to Announce Q4 and Full-Year 2024 Financial ResultsFebruary 7, 2025 | msn.comJennison Associates LLC Has $13.32 Million Stock Position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)Jennison Associates LLC grew its position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 55.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,082,006 shares of the company's stock after pFebruary 6, 2025 | marketbeat.comMineralys Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on Wednesday, February 12, 2025February 5, 2025 | globenewswire.comMineralys Therapeutics Completes Enrollment for Explore-CKD Phase 2 TrialFebruary 5, 2025 | msn.comMineralys completes enrollment for hypertension drug trialFebruary 4, 2025 | msn.comMineralys Therapeutics completes enrollment in Explore-CKD Phase 2 trialFebruary 4, 2025 | markets.businessinsider.comMineralys Therapeutics Completes Enrollment for Key TrialFebruary 4, 2025 | tipranks.comMineralys Therapeutics (NASDAQ:MLYS) Shares Up 5.1% - What's Next?Mineralys Therapeutics (NASDAQ:MLYS) Trading 5.1% Higher - Here's What HappenedJanuary 29, 2025 | marketbeat.comMineralys Therapeutics: Lorundrostat Is Worth A Shot In 2025 For HypertensionJanuary 19, 2025 | seekingalpha.comMineralys Therapeutics, Inc. (NASDAQ:MLYS) Stock Holdings Boosted by Barclays PLCBarclays PLC lifted its position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 281.8% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 38,218 shares of the company's stock after buying an additional 28,208 shares duriJanuary 18, 2025 | marketbeat.comInsider Selling: Mineralys Therapeutics, Inc. (NASDAQ:MLYS) CFO Sells 10,757 Shares of StockJanuary 17, 2025 | insidertrades.comMineralys Therapeutics, Inc. (NASDAQ:MLYS) CFO Sells $97,888.70 in StockMineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) CFO Adam Scott Levy sold 10,757 shares of the firm's stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $9.10, for a total transaction of $97,888.70. Following the completion of the sale, the chief financial officer now owns 226,097 shares of the company's stock, valued at approximately $2,057,482.70. This trade represents a 4.54 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.January 16, 2025 | marketbeat.comJon Congleton Sells 18,333 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) StockJanuary 16, 2025 | insidertrades.comMineralys Therapeutics, Inc. (NASDAQ:MLYS) CEO Sells $166,096.98 in StockMineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) CEO Jon Congleton sold 18,333 shares of the firm's stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $9.06, for a total transaction of $166,096.98. Following the sale, the chief executive officer now owns 877,608 shares of the company's stock, valued at $7,951,128.48. This trade represents a 2.05 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.January 15, 2025 | marketbeat.comMineralys Therapeutics Receives FDA Clearance for Phase 2 Trial of Lorundrostat in Treating Sleep Apnea and HypertensionJanuary 10, 2025 | msn.comMineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with HypertensionJanuary 8, 2025 | finance.yahoo.comMineralys Therapeutics (NASDAQ:MLYS) Shares Down 9.6% - Here's WhyMineralys Therapeutics (NASDAQ:MLYS) Shares Down 9.6% - Time to Sell?January 8, 2025 | marketbeat.comMineralys Therapeutics Advances Lorundrostat to Phase 2 TrialsJanuary 8, 2025 | tipranks.comMineralys Therapeutics (NASDAQ:MLYS) Stock Price Up 4% - What's Next?Mineralys Therapeutics (NASDAQ:MLYS) Shares Up 4% - Time to Buy?December 27, 2024 | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Trading Down 4.1% - Here's WhyMineralys Therapeutics (NASDAQ:MLYS) Shares Down 4.1% - Time to Sell?December 26, 2024 | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Shares Up 3% - Here's WhyMineralys Therapeutics (NASDAQ:MLYS) Shares Up 3% - Still a Buy?December 20, 2024 | marketbeat.comFranklin Resources Inc. Purchases 262,922 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS)Franklin Resources Inc. raised its position in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 17.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,745,513 shares of the company's stock aftDecember 20, 2024 | marketbeat.comWellington Management Group LLP Invests $775,000 in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)Wellington Management Group LLP bought a new stake in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) in the third quarter, according to its most recent Form 13F filing with the SEC. The fund bought 63,998 shares of the company's stock, valued at approximately $775,000. WellingtoDecember 20, 2024 | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Stock Price Down 3.8% - Time to Sell?Mineralys Therapeutics (NASDAQ:MLYS) Trading Down 3.8% - Should You Sell?December 18, 2024 | marketbeat.comPolar Asset Management Partners Inc. Purchases Shares of 40,500 Mineralys Therapeutics, Inc. (NASDAQ:MLYS)Polar Asset Management Partners Inc. acquired a new stake in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 40,500 shares ofDecember 7, 2024 | marketbeat.comCaligan Partners LP Raises Stock Position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)Caligan Partners LP grew its stake in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 31.6% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 981,155 shares of the company's stock after buying an addiDecember 1, 2024 | marketbeat.comMineralys Therapeutics Reports Q3 2024 Results and Clinical ProgressNovember 14, 2024 | msn.comHC Wainwright Has Bearish Estimate for MLYS FY2024 EarningsMineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) - Equities researchers at HC Wainwright reduced their FY2024 EPS estimates for shares of Mineralys Therapeutics in a research note issued on Tuesday, November 12th. HC Wainwright analyst M. Caufield now forecasts that the company will earnNovember 14, 2024 | marketbeat.comLifesci Capital Has Pessimistic View of MLYS FY2024 EarningsMineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) - Research analysts at Lifesci Capital lowered their FY2024 earnings per share (EPS) estimates for Mineralys Therapeutics in a research note issued to investors on Tuesday, November 12th. Lifesci Capital analyst R. Katkhuda now expects thatNovember 14, 2024 | marketbeat.comBuy Rating on Mineralys Therapeutics Driven by Lorundrostat’s Potential in Hypertension TreatmentNovember 13, 2024 | markets.businessinsider.comMineralys Therapeutics, Inc. (NASDAQ:MLYS) Q3 2024 Earnings Call TranscriptNovember 12, 2024 | msn.com Get Mineralys Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLYS and its competitors with MarketBeat's FREE daily newsletter. Email Address MLYS Media Mentions By Week MLYS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MLYS News Sentiment▼0.250.60▲Average Medical News Sentiment MLYS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MLYS Articles This Week▼13▲MLYS Articles Average Week Get Mineralys Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLYS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SDGR News Today NAMS News Today APGE News Today BLTE News Today TVTX News Today IRON News Today WVE News Today IOVA News Today EVO News Today PRAX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MLYS) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredTop Picks for Trump’s Pro-Crypto America10,000% Crypto Opportunities in 2025 27 of the brightest minds in crypto share exclusive intel… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mineralys Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mineralys Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
